In vitro activity of grepafloxacin against Haemophilus influenzae and Moraxella catarrhalis [1]

European Journal of Clinical Microbiology and Infectious Diseases

Volumn 17, Issue 4, 1998, Pages 293-295

  Maskell, J P ^a   Whiley, A C ^a   Sefton, A M ^a  

^a ST BARTHOLOMEW S HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

GREPAFLOXACIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT;

ANTIBACTERIAL ACTIVITY; HAEMOPHILUS INFLUENZAE; LETTER; MORAXELLA CATARRHALIS; NONHUMAN; PRIORITY JOURNAL;

ANTI-INFECTIVE AGENTS; FLUOROQUINOLONES; HAEMOPHILUS INFLUENZAE; MICROBIAL SENSITIVITY TESTS; MORAXELLA (BRANHAMELLA) CATARRHALIS; PIPERAZINES; QUINOLONES;

EID: 0031819708     PISSN: 09349723     EISSN: None     Source Type: Journal    
DOI: 10.1007/s100960050067     Document Type: Letter

References (7)

1. Imada T, Miyazaki S, Nishida M, Yamaguchi K, Goto S: In-vitro and in vivo antibacterial activities of a new quinolone OPC-17116. Antimicrobial Agents and Chemotherapy (1992) 36:573-579.
2. Miyamoto H, Yamashita H, Ueda H, Tamaoka H, Ohmori K, Nakagawa K: Synthesis and biological properties of substituted 1,4-dihydro-5-methyl-4-oxo-3-quinolinecarboxylic acids. Bioorganic and Medicinal Chemistry (1995) 3: 1699-1706.
3. Pankuch GA, Jacobs MR, Appelhaum PC: Activity of CP 99,219 compared with DU-6859a, ciprofloxacin, ofloxacin, levofloxacin, lomefloxacin, tosufloxacin, sparfloxacin and grepafloxacin against penicillin-susceptible and -resistant pneumococci. Journal of Antimicrobial Chemotherapy (1995) 35:230-232.
4. Efthymiopoulos C, Bramer SL, Maroli, A: Pharmacokinetics of grepafloxacin after oral administration of single and repeat doses in healthy young males. Clinical Pharmacokinetics (1997) 33, Supplement 1:1-8.
5. Cook PJ, Andrews JM, Wise R, Honeybourne D, Moudgil H: Concentrations of OPC-17116, a new fluoroquinolone antibacterial, in serum and lung compartments. Journal of Antimicrobial Chemotherapy (1995) 35:317-326.
6. Wakebe H, Imada T, Yoneda H, Mukai F, Ohguro K, Ohmori K, Tamaoka H, Yabuuchi Y: Evaluation of OPC-17116 against important pathogens that cause respiratory tract infections. Antimicrobial Agents and Chemotherapy (1994) 38:2340-2345.
7. Bale MJ, Jones RN, Erwin ME: Minimum inhibitory concentration quality-control guidelines for biapenem, DU-6859a, FK-037, levofloxacin, grepafloxacin and ceftizoxime when using National Committee for Clinical Laboratory Standards susceptibility test methods. Diagnostic Microbiology and Infectious Disease (1994) 19:65-68.